

## Research Article

# mTOR up-regulation of SNRPA1 contributes to hepatocellular carcinoma development

Jing Feng<sup>1,2</sup>, Jian Guo<sup>3</sup>, Pengyu Zhao<sup>1</sup>, Jing Shen<sup>4</sup>, Baofeng Chai<sup>1</sup> and  Junping Wang<sup>2</sup>

<sup>1</sup>Institute of Loess Plateau, Shanxi University, Taiyuan, China; <sup>2</sup>Department of Gastroenterology, Shanxi Provincial People's Hospital, Taiyuan, China; <sup>3</sup>Department of General Surgery, Shanxi Provincial People's Hospital, Taiyuan, China; <sup>4</sup>Department of intervention, Shanxi Provincial People's Hospital, Taiyuan, China

**Correspondence:** Baofeng Chai (bfchai@sxu.edu.cn) or Junping Wang (wangjp8396@sohu.com)



Hepatocellular carcinoma (HCC) is the second leading cause of cancer-related death worldwide. Recent studies showed that snRNPs were implicated in human cancer development. The role of SNRPA1, which is a member of U2 snRNPs, in HCC, remains undocumented. Here, we found that SNRPA1 was highly expressed in HCC tissue compared with normal adjacent liver tissues. Up-regulation of SNRPA1 was correlated with the clinical stage of HCC and the overall survival of HCC patients. *In vitro* and *in vivo* results showed that knockdown of SNRPA1 inhibited the cell proliferation, colony formation and xenografted tumorigenesis of HCC cells. Apoptosis was induced by SNRPA1 down-regulation. Mechanistically, SNRPA1 was stimulated by mTOR activation. In addition, whole-genome microarray analysis identified that 262 genes were up-regulated and 462 genes were down-regulated by SNRPA1 knockdown in HCC cells. qPCR analysis suggested that the fibroblast growth factor-2 (FGF2), Alpha-fetoprotein (AFP),  $\beta$ -catenin, Ki-67 and cyclin B1 were down-regulated and caspase 3, p53 as well as p21 were up-regulated after SNRPA1 knockdown. Taken together, our findings implicate that SNRPA1 functions as an oncogene in HCC.

## Introduction

Hepatocellular carcinoma is fifth most common cancer and the second leading cause of cancer death in worldwide [1,2]. The treatment options are limited and the effectiveness is far from satisfactory with poor prognosis for HCC patients. Understanding the pathogenic factors in tumorigenesis may help explore novel and promising targets for HCC.

Splicing of pre-mRNA into mRNA in eukaryotes is catalyzed by the spliceosome, a multimegadalton ribonucleoprotein complex composed of small nuclear RNAs (snRNAs) and small nuclear ribonucleoproteins (snRNPs) [3,4]. Dysregulation of spliceosome has been reported to participate in diseases development, including retinal degeneration and Taybi-Linder syndrome [5]. Recently, the spliceosome is correlated with cancer progression as mutation of some spliceosome components are found in various cancers, such as chronic lymphocytic leukemia [6], breast cancer [7], lung adenocarcinoma [8], clear cell carcinoma [9] and uveal melanoma [10]. Of note, mutations are detected mainly in U2 snRNPs and U2-related proteins [11]. Although SNRPA1 is one of U2 snRNPs, the role of SNRPA1 in HCC is unclear.

Aberrant activation of mTOR signaling is found in approximately half of HCC cases, largely due to alterations of upstream tumor suppressors and oncogenes, including PI3K, AKT, PTEN and TSC1/2 [12]. Ribosomal protein S6 kinase beta-1 (S6K1) and eukaryotic initiation factor 4E-binding protein 1 (4E-BP1) are well-known downstream targets of mTOR signaling pathway that regulate ribosome RNA biogenesis and protein synthesis, therefore functioning as a critical regulator in tumor cell proliferation, motility, invasion and cancer metastasis [13,14]. Even though a large amount of studies have revealed the molecular mechanisms of mTOR-induced HCC development, little is known about the association between mTOR and SNRPA1.

Received: 12 November 2019  
 Revised: 05 May 2020  
 Accepted: 14 May 2020

Accepted Manuscript online:  
 18 May 2020  
 Version of Record published:  
 15 June 2020

**Table 1** The association between clinical characteristics and SNRPA1 expression

		SNRPA1 expression		Total	P value
		Low	High		
Grade	G1/2	136	96	232	<b>.000</b>
	G3/4	46	88	134	
Total		182	184	366	
T Stage	T1	101	80	181	<b>.020</b>
	T2	43	51	94	
	T3/4	39	54	93	
Total		183	185	368	
AJCC Stage	Stage I	92	79	171	.052
	Stage II	38	48	86	
	Stage III/IV	38	52	90	
Total		168	179	347	

Since SNRPA1 was highly expressed in HCC tissues and its up-regulation was correlated with the HCC stage and patients' overall survival, the function and mechanistic basis of SNRPA1 in HCC development should be determined. Herein, we aimed to investigate the *in vitro* and *in vivo* function and related molecular mechanism of SNRPA1 in HCC. Knockdown of SNRPA1 induced the apoptosis and inhibited the proliferation, colony formation and xenografting tumorigenesis of HCC cells. SNRPA1 expression was increased by mTOR activation. Furthermore, SNRPA1 knockdown caused alterations of numerous genes, among which HCC biomarker, AFP, was down-regulated.

## Methods

### TCGA gene expression data

SNRPA1 mRNA expression and clinical information of HCC patients were downloaded from The Cancer Genome Atlas at <http://cancergenome.nih.gov>. The 543 samples, which contain 373 tumor tissues and 169 adjacent normal liver tissues (located >5 cm from the tumor tissues), were available for the present study. In Table 1, grade represents the cell differentiation extent (G1/G2 is well/ moderately differentiated; G3/G4 represents poorly differentiated/ anaplastic). And T stage represents tumor stage. AJCC is an abbreviation for the American Joint Committee on Cancer, which was refined and well described previously [15]. For survival analysis, HCC patients were ranked by SNRPA1 mRNA expression from the highest to the lowest. Then, they were equally divided into two groups, among which each patient in the high SNRPA1 expression group had higher SNRPA1 expression than those in the low SNRPA1 expression group. Several samples were removed due to missing survival information.

### Cell lines

The human normal liver LO2 cells and HCC cell lines BEL-7404, SMMC-7721, HepG2 and SMMC-7721 were obtained from Cell Bank of the Chinese Academy of Sciences (Shanghai, China). All cells were maintained in Dulbecco modified Eagle's medium (DMEM, Invitrogen), containing 10% fetal bovine serum (Gibco), 1% penicillin and streptomycin solution (Corning). The cells were cultured in a 37°C incubator with 5% CO<sub>2</sub>.

### SNRPA1 and TSC2 knockdown assay

Lentivirus vector pGCSIL-GFP was applied to knock down indicated genes in HCC cells. The targeted sequences were as follows: shSNRPA1, 5'-TACGTTAGACCAGTTTGAT-3'; shTSC2, 5'-GCATGGAATGTGGCCTCAA-3'; shCtrl, 5'-TTCTCCGAACGTGTCACGT-3'. Briefly, shRNA was synthesized and cloned into pGCSIL-GFP vector and then transfected into 293T cells using Lipofectamine TM 2000 (Invitrogen, Shanghai, China), accompanied with pHelper1.0 and Helper2.0. Forty-eight hours after transfection, lentiviral supernatants were collected and filtered through 0.45 µm filters, and then concentrated by ultracentrifugation at 50,000 g for 2.5 h at 4°C. The virus was used to infect BEL-7404 and SMMC-7721 cells. qRT-PCR and Western blot assays were used to examine the knockdown efficiency.

### siRNA interference

siRNA targeting the human Raptor, Rictor and negative control were synthesized by GenePharma (Shanghai, China). When TSC2 silencing BEL-7404 cells were seeded in 60-mm plates to reach 30–50% confluency, they were

transfected with 100 nM siRNA using Lipofectamine 2000 (Invitrogen), according to the manufacturer's instructions. Forty-eight hours later, cells were lysed and subjected to Western blot with indicated antibodies.

## Total RNA isolation and quantitative real-time PCR

Total RNA was isolated using Trizol reagent (Invitrogen) and RNeasy Mini kit (QIAGEN) as described by the manufacturer. RNA quality and quantity were measured by running RNA on agarose gels and DanoDrop (Thermo fisher). RNA was reversely transcribed using ReverTra Ace<sup>®</sup> qPCR RT Master Mix with gDNA Remover (TOYOBO). The cDNA was subjected to quantitative real-time PCR (qRT-PCR) on an IQ-5 machine using TransStart Top Green qPCR SuperMix (TransGen Biotech) to detect mRNA expression levels of indicated genes. qRT-PCR primer sequences were as follow: FGF2 forward, 5'-AGTGTGTGCTAACCGTTACCT-3' and reverse, 5'-ACTGCCAGTTTCGTTTCAGTG-3'; AFP forward, 5'-AGTGAGGACAACTATTGGCCT-3' and reverse, 5'-ACACCAGGGTTTACTGGAGTC-3';  $\beta$ -catenin forward, 5'-CATCTACACAGTTTGATGCTGCT-3' and reverse, 5'-GCAGTTTTGTTCAGTTTCAGGGA-3'; Ki-67 forward, 5'-AGAAGAAGTGGTGCTTCGGAA-3' and reverse, 5'-AGTTTGCCTGGCCTGTACTAA-3'; cyclin B1 forward, 5'-TTGGGGACATTGGTAACAAAGTC-3' and reverse, 5'-ATAGGCTCAGGCGAAAGTTT-3'; P53 forward, 5'-ACAGCTTTGAGGTGCGTGT-3' and reverse, 5'-CCCTTCTTGCGGAGATTCTCT-3'; P21 forward, 5'-CGATGGAAGTTCGACTTTGTCA-3' and reverse, 5'-GCACAAGGGTACAAGACAGTG-3'; caspase 3 forward, 5'-AGAGGGGATCGTTGTAGAAGTC-3' and reverse, 5'-ACAGTCCAGTTCTGTACCACG-3'; GAPDH forward, 5'-TGAAGTCAACAGCGACACCCA-3' and reverse, 5'-CACCCTGTTGCTGTAGCCAAA-3'. The results were normalized to GAPDH.

## Western blot

Whole-cells were lysed using lysis buffer (Beyotime) on ice for 30 min and centrifuged at  $13,000 \times g$  for 20 min. Protein concentration was determined using a BCA protein assay kit (Beyotime). Forty micrograms of protein mixed with SDS sample buffer was separated by 12% concentrated polyacrylamide gel and then transferred to polyvinylidene fluoride membrane (PVDF; Millipore, U.S.A.). After protein transfer, the membranes were blocked with 5% skim milk for 1 h in TBST (TBS containing 0.1% Tween 20) and incubated at 4°C overnight with primary antibodies against p-S6 (#4858), S6 (#2317), Raptor (#2280) and Rictor (#2114), SNRPA1 (ab128937), and GAPDH. All the secondary antibodies were purchased from Santa Cruze.

## High-content screening for cell proliferation assay

Cell proliferation was measured using multiparametric high-content screening (HCS) assay. BEL-7404 and SMMC-7721 cells expressing shCtrl or shSNRPA1 were maintained in 96-well plates for 5 days. Stained cells were analyzed by the ArrayScan<sup>™</sup> HCS system (Cellomics Inc). This system is a fluorescence-imaging microscope that automatically identifies stained cells and detects the intensity and distribution of fluorescence in single cells [16]. Images were acquired and analyzed using suitable filters by  $20\times$  objective.

## MTT for cell proliferation assay

BEL-7404 cells and SMMC-7721 cells expressing shCtrl or shSNRPA1 were seeded into 96-well plates (2000 cells per well) and maintained for 1, 2, 3, 4 and 5 days. Each well was washed by PBS for three times and 3-(4,5-dimethyl-2-yl)-2,5-diphenyltetrazolium bromide (MTT) solution (5 mg/ml) was added to each well. Three hours later, the supernatants were removed and 150  $\mu$ l dimethyl sulfoxide (DMSO) was added. Ten minutes later, the OD was determined at 490 nm on a microplate reader.

## Colony formation assay

shCtrl or shSNRPA1 BEL-7404 cells and SMMC-7721 cells were seeded in six-well dishes at a concentration of 800 cells per well. After cultured at 37°C for 12 days, cell colonies were formed. The colonies were fixed with methanol for at least 30 min and stained with Giemsa solution for 15 min. The number of colonies ( $>50$  cells/colony) was manually counted by the microscopy (Olympus).

## Apoptosis assay

Apoptosis was measured using Annexin V-APC apoptosis detection kit (Ebioscience, U.S.A.) following the manufacturer's instruction. BEL-7404 cells or SMMC-7721 cells infected with shCtrl or shSNRPA1 lentiviruses were washed twice with PBS, and then were re-suspended with 5  $\mu$ l annexin V-APC and 100  $\mu$ l cell suspension at room

**Table 2 Multivariate Cox regression analysis of overall survival for patients with HCC**

	HR	95% CI	P
SNRPA1 expression	1.871	1.165–3.003	.010
Race	2.614	1.521–4.494	.001

Abbreviations: CI, confidence interval; HR, hazard ratio.

temperature. Fifteen minutes later, the cells were subjected to apoptosis analysis on flow cytometry (FACS Calibur, Becton-Dickinson, U.S.A.).

### **In vivo xenograft assay**

Female athymic BALB/C nude mice (4 weeks old) were purchased from the Vital River Co., LTD (Beijing, China). A total of  $4 \times 10^6$  BEL-7404 cells infected with shCtrl or shSNRPA1 virus were subcutaneously injected into the right armpit of mice (ten mice for each group). Tumor growth was monitored and tumor size was measured until day 27 after implantation. By day 27, mice were killed by carbon dioxide euthanasia, according to the protocols as described previously [17]. The lid was closed immediately after introducing 100% carbon dioxide into the cages. The mice will die within 2.5 min. Then, the tumors were excised, weighed and fixed in formalin. The volume of xenograft tumors was calculated following the formula: volume =  $0.5 (\text{length} \times \text{width}^2)$ . The animal experiments were completed at the Laboratory Animal Center of Shanxi Provincial People's Hospital. The present study was approved by the Ethics Committee of Shanxi Provincial People's Hospital. All animal studies were conducted in accordance with Institutional Animal Care and Use Committee guidelines of Shanxi Provincial People's Hospital.

### **Microarray**

Total RNA was extracted from shCtrl ( $n=3$ ) or shSNRPA1 ( $n=3$ ) BEL-7404 cells using Trizol reagents. The quantity and purity of isolated RNA were measured by NanoDrop 2000 and Agilent Bioanalyzer 2100. The gene expression profile was determined using Affymetrix human GeneChip primeview, following the manufacturer's instruction. Significantly dysregulated genes in shSNRPA1 BEL-7404 cells compared with those in shCtrl cells were identified with the following criteria:  $P < 0.05$  and the absolute fold change  $> 1.5$ . The biofunction and pathway enrichment analysis were performed using IPA<sup>®</sup> Software (<http://www.ingenuity.com>).


### **Statistical analysis**

The statistical analysis was performed using GraphPad Prism 6.0 software. The results were represented as the mean  $\pm$  standard error of mean (SEM) of at least three independent samples. Students' *t*-test were used to analyze the difference between two groups. One-way ANOVA was used when more than two groups. Difference was considered significant when the *P*-value was  $< 0.05$ .

## **Results**

### **SNRPA1 is up-regulated in HCC tissues and correlated with the overall survival of HCC patients**

First, we investigated the clinical relevance of SNRPA1 by analyzing the expression of HCC-related SNRPA1 in TCGA database. The results showed that SNRPA1 expression was obviously up-regulated in HCC tissues compared with the normal tissues (Figure 1A). We then sought to examine the abundance of SNRPA1 in 50 HCC tissues and corresponding normal liver tissues. The results showed that SNRPA1 was up-regulated in HCC tissues (Figure 1B). Furthermore, we explored the correlation between the elevated SNRPA1 expression and clinicopathological features of HCC patients. As shown in Table 1, SNRPA1 up-regulation was strongly associated with T stage ( $P < 0.05$ ). In addition, Kaplan–Meier survival analyses were performed to evaluate the relationship between SNRPA1 expression and the overall survival of HCC patients. The 369 HCC patients were divided into SNRPA1 high expression group and SNRPA1 low expression group. The results revealed that the overall survival time was poorer in SNRPA1 highly expressed patients than in SNRPA1 lowly expressed patients (Figure 1C). We also employed Multivariate Cox Regression Analysis of Overall Survival for Patients with HCC. The results showed that SNRPA1 high expression was an independent prognostic factor for HCC patients (Table 2). Additionally, the expression of SNRPA1 was increased in different HCC cells comparing with normal liver cells LO2 (Figure 1D). Collectively, these findings suggest that SNRPA1 is closely associated with HCC.




**Figure 1. SNRPA1 expression is increased in HCC specimens and is correlated with the overall survival of HCC patients**  
(A) SNRPA1 relative expression in 373 HCC and 169 normal tissues was analyzed from the Cancer Genome Atlas (TCGA) database (Fold Change (FC) = 1.0,  $P < 0.05$ ). (B) SNRPA1 expression in HCC and adjacent liver tissues was analyzed from the Cancer Genome Atlas (TCGA) database ( $n=50$ ,  $P=3.00E-5$ ). (C) Overall survival of HCC patients with high or low SNRPA1 expression;  $P < 0.05$ . (D) SNRPA1 mRNA expression in LO2, BEL-7404, BEL-7402, HepG2 and SMMC-7721 cells;  $*P < 0.05$ .

## SNRPA1 knockdown suppresses HCC cells proliferation and growth

Based on the clinical relevance of SNRPA1 in HCC, we next assessed the biological functions of SNRPA1 in HCC by knocking down SNRPA1 in HCC cells, including SMMC-7721 and BEL-7404. qRT-PCR and Western blot were performed to determine SNRPA1 knockdown efficiency by lentivirus-mediated shRNA strategy. The results showed that SNRPA1 was silenced in both SMMC-7721 and BEL-7404 cells (Figure 2). Then, we measured cell proliferation using high-content screening assay and found that SNRPA1 knockdown significantly suppressed the growth of BEL-7404 cells (Figure 3A,B). MTT assays showed that the viability of BEL-7404 cells was retarded by SNRPA1 silencing (Figure 3E). We further examined the function of SNRPA1 in another HCC cells SMMC-7721. Consistently, SNRPA1 silencing inhibited the proliferation of SMMC-7721 cells (Figure 3C,D,F).






**Figure 2. SNRPA1 is efficiently silenced in BEL-7404 and SMMC-7721 cells**

(A and B) shCtrl or shSNRPA1 BEL-7404 cells were subjected to qRT-PCR (A) and Western blot (B) analysis of SNRPA1. GAPDH serve as internal control;  $^{**}P < 0.01$ . (C and D) shCtrl or shSNRPA1 SMC-7721 cells were subjected to qRT-PCR (C) and Western blot (D) analysis of SNRPA1. GAPDH serve as internal control;  $^{**}P < 0.01$ .

To confirm the effect of SNRPA1 knockdown on HCC cell growth, we subjected shCtrl and shSNRPA1 BEL-7404 cells or SMMC-7721 cells to colony formation assay. We observed that SNRPA1 silencing almost completely blunted the colony formation of BEL-7404 cells (Figure 3G,H). To a less extent, colony growth was also repressed by SNRPA1 knockdown in SMMC-7721 cells (Figure 3I,J). Taken together, these results indicate that SNRPA1 is critical for the proliferation and growth in HCC cells.

### SNRPA1 is required for tumorigenesis of BEL-7404 cells in nude mice

To explore the *in vivo* role of SNRPA1, we subcutaneously implanted shCtrl or shSNRPA1 BEL-7404 cells into nude mice and evaluated the tumorigenesis. We found that SNRPA1 knockdown inhibited tumor growth of BEL-7404 cells (Figure 4A). Tumor volume was reduced by SNRPA1 knockdown comparing with Ctrl group (Figure 4B). In addition, the average tumor weight of shSNRPA1 cells was obviously lower than that of shCtrl cells (Figure 4C). These results demonstrate that SNRPA1 knockdown blunts the tumorigenic capacity of BEL-7404 cells *in vivo*.




**Figure 3. SNRPA1 knockdown inhibits the proliferation and colony formation of BEL-7404 and SMMC-7721 cells**

(A) Photographs of multiparametric high-content screening (HCS) of shCtrl (top) and shSNRPA1 (bottom) BEL-7404 cells from day 1 to day 5. (B) Quantification of the HCS results;  $^{**}P < 0.01$ ,  $^{***}P < 0.001$ . (C) Photographs of multiparametric high-content screening (HCS) of shCtrl (top) and shSNRPA1 (bottom) SMMC-7721 cells from day 1 to day 5. (D) Quantification of the HCS results;  $^{**}P < 0.01$ ,  $^{***}P < 0.001$ . (E) Cell proliferation of shCtrl or shSNRPA1 BEL-7404 cells was determined by MTT assay;  $^{**}P < 0.01$ ,  $^{***}P < 0.001$ . (F) Cell proliferation of shCtrl or shSNRPA1 SMMC-7721 cell was determined by MTT assay;  $^{**}P < 0.01$ ,  $^{***}P < 0.001$ . (G) Representative photographs of cell colony. (H) Quantification of the colony numbers;  $^{**}P < 0.01$ . (I) Representative photographs of cell colony. (J) Quantification of the colony numbers;  $^{**}P < 0.01$ .


## Depletion of SNRPA1 increases HCC cells apoptosis *in vitro*

To explore the role of SNRPA1 in apoptosis, BEL-7404 and SMMC-7721 cells expressing shCtrl or shSNRPA1 lentivirus were harvested and examined by flow cytometry. Depletion of SNRPA1 significantly induced apoptosis in both BEL-7404 and SMMC-7721 cells (Figure 5A–D). Thus, we speculated that SNRPA1 knockdown may inhibit the viability of HCC cells partly through inducing apoptosis.



**Figure 4. SNRPA1 is required for tumorigenesis of BEL-7404 cells in nude mice**


(A) The photographs of xenograft tumors from nude mice 27 days after shCtrl or shSNRPA1 BEL-7404 cells transplantation ( $n=10$ ). (B) Tumor volume of xenograft tumors in nude mice from day 1 to day 27;  $v = 0.5ab^2$  ( $a$ : long diameter,  $b$ : short diameter); ( $n=10$ ), \* $P < 0.05$ , \*\* $P < 0.01$ . (C) The weight of xenograft tumors by day 27 after transplantation ( $n=10$ ); \* $P < 0.05$ .



**Figure 5. Depletion of SNRPA1 increases HCC cells apoptosis *in vitro***

Flow cytometry detection of apoptosis in shCtrl or shSNRPA1 BEL-7404 cells. (A) Flow cytometry analysis of apoptosis. (B) Quantification of apoptosis. \*\* $P < 0.01$ . (C,D) Flow cytometry detection of apoptosis in shCtrl or shSNRPA1 SMC-7721 cells. (C) Flow cytometry analysis of apoptosis. (D) Quantification of apoptosis. \*\* $P < 0.01$ .





**Figure 6. SNRPA1 is activated by mTORC1 in HCC cells**


TSC2 silencing or Ctrl BEL-7404 cells were treated with or without (5 nM) rapamycin and then subjected to qRT-PCR (A) and Western blot (B) analysis of SNRPA1. S6 serve as internal control; \* $P < 0.05$ , \*\*\* $P < 0.001$ . Raptor (C) or Rictor (D) were further knocked down in TSC2 silencing BEL-7404 cells and the cells were subjected to Western blot and qRT-PCR analysis of indicated genes. S6 serve as internal control; \*\* $P < 0.01$ . n.s., no significance.

## SNRPA1 expression is activated by mTORC1 in HCC cells

mTOR signaling is frequently hyper-activated in HCC. We then explored the potential association between SNRPA1 expression and mTOR signaling pathway. We found that silencing of TSC2 could cause mTOR activation, as showed by elevated phosphorylation level of S6 (Figure 6B). In addition, TSC2 knockdown elevated the expression of SNRPA1 in both mRNA and protein levels, which could be efficiently suppressed by rapamycin treatment (Figure 6A,B). These results indicated that the activation of mTOR promoted SNRPA1 expression in HCC cells. As mTOR forms the catalytic subunit of two separate multi-protein complexes, referred to mTOR Complex 1 (mTORC1) and mTOR Complex 2 (mTORC2), which complex contributed to SNRPA1 stimulation should be addressed. Thus, we silenced Raptor or Rictor in TSC2 knockdown HCC cells and found that depletion of Raptor decreased the upregulated SNRPA1 in TSC2 silencing HCC cells, while Rictor knockdown had no effect (Figure 6C,D). Our results suggested that mTORC1 activation enhances SNRPA1 expression in HCC cells.

## SNRPA1 knockdown cause dysregulation of numerous genes

To investigate the potential downstream targets responsible for the biological activity of SNRPA1 in HCC, we conducted GeneChip analysis in shCtrl and shSNRPA1 BEL-7404 cells. The significantly dysregulated genes were defined following the criteria: fold change  $> 1.5$  and  $P < 0.05$ . Heatmap results showed that a total of 262 genes including several oncogenes were up-regulated and 462 genes including some tumor suppressors, and genes relating to the iNOS pathway were downregulated by SNRPA1 knockdown (Figure 7A). Furthermore, the ingenuity canonical pathways enrichment analyses showed that genes in the iNOS pathway were significantly suppressed by SNRPA1 knockdown in BEL-7404 cells ( $-\log(P\text{-value}) = 1.36$ ,  $Z\text{-score} = -2$ ; Figure 7B). To validate the microarray assay results, we measured the mRNA expression of several genes differential expressed in microarray by qRT-PCR assay. Our results showed that fibroblast growth factor-2 (FGF2), alpha-fetoprotein (AFP),  $\beta$ -catenin, Ki-67 and cyclin B1 were down-regulated after SNRPA1 knockdown in BEL-7404 cells (Figure 7C). Conversely, caspase 3, p53 and p21 were up-regulated in shSNRPA1 cells compared with shCtrl BEL-7404 cells (Figure 7C). Collectively, our results suggest



**Figure 7. Dysregulated genes in BEL-7404 cells after SNRPA1 knockdown**

(A) Heatmap of 724 differentially expressed genes (262 genes up-regulated and 462 genes down-regulated,  $P < 0.05$  and absolute fold change  $> 1.5$ ) in BEL-7404 cells infected with shCtrl or shSNRPA1 lentivirus. Samples were listed in columns, and genes were listed in rows. Greens represented down-regulated genes, while red ones represented up-regulated genes. (B) Pathway enrichment analysis using IPA software showed that iNOS signaling was dramatically suppressed after SNRPA1 knockdown. (C) qRT-PCR analysis of FGF2, AFP,  $\beta$ -catenin, Ki-67, cyclin B1, P53, P21 and caspase 3 in shCtrl or shSNRPA1 BEL-7404 cells;  $*P < 0.05$ .

that SNRPA1 silencing may suppress HCC development via iNOS signaling pathway, as well as numerous oncogenes and tumor suppressors.

## Discussion

In the present study, we found that of SNRPA1 expression was up-regulated in HCC tissues compared with normal liver tissues. SNRPA1 expression was associated with not only the clinical T stage of HCC, but also the overall survival of HCC patients. Depletion of SNRPA1 promoted apoptosis and suppressed the proliferation, growth and xenografting tumorigenesis in HCC. Additionally, mTORC1 activation potentiated the expression of SNRPA1 in HCC cells. Knockdown of SNRPA1 caused dysregulation of several important oncogenes and tumor suppressors and iNOS pathway in HCC cells.

SNRPA1 is a U2 snRNPs belonging to the spliceosome family that regulates the splicing of pre-mRNA into mRNA. Although some evidences have shown that spliceosome may play a key role in cancer development, little is known about the biological function of SNRPA1 in HCC. TCGA data showed that SNRPA1 was significantly overexpressed in HCC tissues and its expression was inversely associated with the disease prognosis. In addition, the mRNA expression of SNRPA1 was relatively higher in HCC cells than in normal liver cells LO2. Because we intended to explore the function of SNRPA1 in HCC, we silenced SNRPA1 in HCC cells BEL-7404 and SMMC-7721 and subjected them to cell proliferation, apoptosis and tumor growth analysis. We observed that depletion of SNRPA1 in BEL-7404 and SMMC-7721 cells largely reduced HCC cell viability. Nude mice experiments also demonstrated the essential contribution of SNRPA1 in tumor formation. It is well known that suppressed apoptosis leads to a state of uncontrolled proliferation of cancer cells. Here, SNRPA1 knockdown increased the apoptosis of both BEL-7404 and SMMC-7721 cells, suggesting that SNRPA1 knockdown inhibits the viability of HCC cells partly through inducing apoptosis.

Hyper-activation of mTOR signaling is frequently observed in human HCC tissues, mainly caused by dysregulation of upstream tumor suppressors, such as PTEN or TSC1/2 [12]. Evidences have shown that mTOR activation is sufficient to induce HCC development in mice [18,19]. Even though rapamycin, an inhibitor of mTOR, effectively reduces HCC with mTOR activation [18], long-term usage of rapamycin in a HCC mouse model causes liver injury, inflammation and subsequently higher tumor burden [20]. Rapamycin has been widely used in clinic for tumors, whereas the outcomes of rapamycin treatment in HCC remain far from satisfactory. Therefore, exploring the potential downstream targets may help us develop promising therapeutic targets for HCC. Here, we revealed that mTOR activation stimulated SNRPA1. Rapamycin treatment reversed the up-regulated SNRPA1 in HCC cells. Knockdown of Raptor, a member of mTORC1, suppressed the highly expressed SNRPA1 in TSC2 silencing HCC cells, while silencing of Rictor, a component of mTORC2, had no effect. We suggested that mTORC1 activation promoted SNRPA1 expression.

Because SNRPA1 regulates the splicing of pre-mRNA into mRNA, we next attempted to detect dys-regulated genes after SNRPA1 knockdown. Our GeneChip results showed that a total of 262 genes were up-regulated and 462 genes were down-regulated in shSNRPA1 compared with shCtrl BEL-7404 cells. Among these alterations, iNOS pathway was significantly inhibited. Overexpression of iNOS has been found in various cancers, including ovarian cancer [21], lung cancer [22] and osteosarcoma [23]. Thus, iNOS pathway may contribute to SNRPA1-mediated HCC development. It has been demonstrated that FGF2 stimulates HCC proliferation, invasion, and induces angiogenesis [24]. A novel FGF2 monoclonal antibody effectively suppressed the growth of hepatocellular carcinoma xenografts [25].  $\beta$ -catenin is the second oncogene in HCC [26,27]. AFP is a well-known biomarker for HCC [28,29]. Here, we found that SNRPA1 knockdown in BEL-7404 cells resulted in down-regulation of FGF2,  $\beta$ -catenin, AFP, Ki-67 and cyclin B1. Additionally, apoptosis and cell cycle-associated genes, caspase 3, p53 and p21 were up-regulated by SNRPA1 silencing. These altered genes might explain why SNRPA1 silencing suppresses the proliferation and tumor formation of HCC cells. However, we still need further investigate which gene regulated by SNRPA1 is critical for HCC development.

In conclusion, we provided the first evidence that SNRPA1 functioned as an oncogene in HCC. SNRPA1 was up-regulated in HCC tissues and its expression was significantly correlated with the prognosis of the HCC patients. SNRPA1 silencing inhibited the proliferation and tumorigenesis of HCC cells. Mechanistically, SNRPA1 was stimulated by mTOR activation and it regulated various oncogenes and tumor suppressors. Our study suggests that SNRPA1 may serve as a promising target for HCC. Further study is needed to investigate the underlying mechanism by which SNRPA1 regulates proliferation and apoptosis.

## Summary

Hepatocellular carcinoma is one of the most common malignancies in the world. Here we identify SNRPA1, which is active by mTOR signaling, as an oncogenic protein and a poor prognostic factor in hepatocellular carcinoma to promote cell proliferation and survival.

## Competing Interests

The authors declare that there are no competing interests associated with the manuscript.

## Funding

This work was supported by grants from the National Natural Science Foundation of China [grant number 31772450].

## Author Contribution

Baofeng Chai and Junping Wang conceived the study, carried out the experimental design and data interpretation, and prepared and revised the manuscript. Feng Jing performed most of the experiments. Jian Guo performed the HCS assay. Pengyu Zhao performed the Western blot. Jing Shen performed microarray assay.

## Abbreviations

4E-BP, eukaryotic initiation factor 4E-binding protein 1; AFP, Alpha-fetoprotein; AKT, AKT serine/threonine kinase; DMEM, Dulbecco modified Eagle's medium; DMSO, dimethyl sulfoxide; FGF2, fibroblast growth factor-2; HCC, hepatocellular carcinoma; HCS, high-content screening; iNOS, inducible nitric oxide synthase; mTOR, mammalian target of rapamycin; MTT, 3-(4,5-dimethyl-2-yl)-2,5-diphenyltetrazolium bromide; PI3K, phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta; PTEN, gene of phosphate and tension homology deleted on chromosome ten; PVDF, polyvinylidene fluoride; S6K1, protein

S6 kinase beta-1; shRNA, short hairpin RNA; snRNA, small nuclear RNA; snRNP, small nuclear ribonucleoprotein; TCGA, The Cancer Genome Atlas; TSC1/2, tuberous sclerosis 1/2.

## References

- Jemal, A., Bray, F., Center, M.M., Ferlay, J., Ward, E. and Forman, D. (2011) Global cancer statistics. *CA Cancer J. Clin.* **61**, 69–90, <https://doi.org/10.3322/caac.20107>
- El-Serag, H.B. (2011) Hepatocellular carcinoma. *N. Engl. J. Med.* **365**, 1118–27, <https://doi.org/10.1056/NEJMra1001683>
- Reed, R., Griffith, J. and Maniatis, T. (1988) Purification and visualization of native spliceosomes. *Cell* **53**, 949–61, [https://doi.org/10.1016/S0092-8674\(88\)90489-8](https://doi.org/10.1016/S0092-8674(88)90489-8)
- Wahl, M.C., Will, C.L. and Luhrmann, R. (2009) The spliceosome: design principles of a dynamic RNP machine. *Cell* **136**, 701–18, <https://doi.org/10.1016/j.cell.2009.02.009>
- Singh, R.K. and Cooper, T.A. (2012) Pre-mRNA splicing in disease and therapeutics. *Trends Mol. Med.* **18**, 472–82, <https://doi.org/10.1016/j.molmed.2012.06.006>
- Quesada, V., Conde, L., Villamor, N., Ordonez, G.R., Jares, P., Bassaganyas, L. et al. (2011) Exome sequencing identifies recurrent mutations of the splicing factor SF3B1 gene in chronic lymphocytic leukemia. *Nat. Genet.* **44**, 47–52, <https://doi.org/10.1038/ng.1032>
- Ellis, M.J., Ding, L., Shen, D., Luo, J., Suman, V.J., Wallis, J.W. et al. (2012) Whole-genome analysis informs breast cancer response to aromatase inhibition. *Nature* **486**, 353–60, <https://doi.org/10.1038/nature11143>
- Imielinski, M., Berger, A.H., Hammerman, P.S., Hernandez, B., Pugh, T.J., Hodis, E. et al. (2012) Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing. *Cell* **150**, 1107–20, <https://doi.org/10.1016/j.cell.2012.08.029>
- Sato, Y., Yoshizato, T., Shiraishi, Y., Maekawa, S., Okuno, Y., Kamura, T. et al. (2013) Integrated molecular analysis of clear-cell renal cell carcinoma. *Nat. Genet.* **45**, 860–7, <https://doi.org/10.1038/ng.2699>
- Harbour, J.W., Roberson, E.D., Anbunathan, H., Onken, M.D., Worley, L.A. and Bowcock, A.M. (2013) Recurrent mutations at codon 625 of the splicing factor SF3B1 in uveal melanoma. *Nat. Genet.* **45**, 133–5, <https://doi.org/10.1038/ng.2523>
- Yoshida, K., Sanada, M., Shiraishi, Y., Nowak, D., Nagata, Y., Yamamoto, R. et al. (2011) Frequent pathway mutations of splicing machinery in myelodysplasia. *Nature* **478**, 64–9, <https://doi.org/10.1038/nature10496>
- Zucman-Rossi, J. (2010) Molecular classification of hepatocellular carcinoma. *Digestive Liver Dis.: Off. J. Italian Soc. Gastroenterol. Italian Assoc. Study Liver* **42**, S235–S241, [https://doi.org/10.1016/S1590-8658\(10\)60511-7](https://doi.org/10.1016/S1590-8658(10)60511-7)
- Khaleghpour, K., Pyronnet, S., Gingras, A.C. and Sonenberg, N. (1999) Translational homeostasis: eukaryotic translation initiation factor 4E control of 4E-binding protein 1 and p70 S6 kinase activities. *Mol. Cell. Biol.* **19**, 4302–10, <https://doi.org/10.1128/MCB.19.6.4302>
- Kimball, S.R., Shantz, L.M., Horetsky, R.L. and Jefferson, L.S. (1999) Leucine regulates translation of specific mRNAs in L6 myoblasts through mTOR-mediated changes in availability of eIF4E and phosphorylation of ribosomal protein S6. *J. Biol. Chem.* **274**, 11647–52, <https://doi.org/10.1074/jbc.274.17.11647>
- Subramaniam, S., Kelley, R.K. and Venook, A.P. (2013) A review of hepatocellular carcinoma (HCC) staging systems. *Chin. Clin. Oncol.* **2**, 33
- Nierode, G., Kwon, P.S., Dordick, J.S. and Kwon, S.J. (2016) Cell-Based Assay Design for High-Content Screening of Drug Candidates. *J. Microbiol. Biotechnol.* **26**, 213–25, <https://doi.org/10.4014/jmb.1508.08007>
- Liu, L., Yan, Y., Zhang, G., Chen, C., Shen, W. and Xing, P. (2020) Knockdown of LINC01694 inhibits growth of gallbladder cancer cells via miR-340-5p/Sox4. *Biosci. Rep.* **40**, <https://doi.org/10.1042/BSR20194444>
- Menon, S., Yecies, J.L., Zhang, H.H., Howell, J.J., Nicholatos, J., Harputlugil, E. et al. (2012) Chronic activation of mTOR complex 1 is sufficient to cause hepatocellular carcinoma in mice. *Sci. Signal* **5**, ra24, <https://doi.org/10.1126/scisignal.2002739>
- Kenerson, H.L., Yeh, M.M., Kazami, M., Jiang, X., Riehle, K.J., McIntyre, R.L. et al. (2013) Akt and mTORC1 have different roles during liver tumorigenesis in mice. *Gastroenterology* **144**, 1055–65, <https://doi.org/10.1053/j.gastro.2013.01.053>
- Umemura, A., Park, E.J., Taniguchi, K., Lee, J.H., Shalapour, S., Valasek, M.A. et al. (2014) Liver damage, inflammation, and enhanced tumorigenesis after persistent mTORC1 inhibition. *Cell Metab.* **20**, 133–44, <https://doi.org/10.1016/j.cmet.2014.05.001>
- Qiu, H., Orr, F.W., Jensen, D., Wang, H.H., McIntosh, A.R., Hasinoff, B.B. et al. (2003) Arrest of B16 melanoma cells in the mouse pulmonary microcirculation induces endothelial nitric oxide synthase-dependent nitric oxide release that is cytotoxic to the tumor cells. *Am. J. Pathol.* **162**, 403–12, [https://doi.org/10.1016/S0002-9440\(10\)63835-7](https://doi.org/10.1016/S0002-9440(10)63835-7)
- Zhang, L., Liu, J., Wang, X., Li, Z., Zhang, X., Cao, P. et al. (2014) Upregulation of cytoskeleton protein and extracellular matrix protein induced by stromal-derived nitric oxide promotes lung cancer invasion and metastasis. *Curr. Mol. Med.* **14**, 762–71, <https://doi.org/10.2174/1566524014666140724103147>
- Klotz, T., Bloch, W., Volberg, C., Engelmann, U. and Addicks, K. (1998) Selective expression of inducible nitric oxide synthase in human prostate carcinoma. *Cancer* **82**, 1897–903, [https://doi.org/10.1002/\(SICI\)1097-0142\(19980515\)82:10%3C1897::AID-CNCR12%3E3.0.CO;2-0](https://doi.org/10.1002/(SICI)1097-0142(19980515)82:10%3C1897::AID-CNCR12%3E3.0.CO;2-0)
- Kin, M., Sata, M., Ueno, T., Torimura, T., Inuzuka, S., Tsuji, R. et al. (1997) Basic fibroblast growth factor regulates proliferation and motility of human hepatoma cells by an autocrine mechanism. *J. Hepatol.* **27**, 677–87, [https://doi.org/10.1016/S0168-8278\(97\)80085-2](https://doi.org/10.1016/S0168-8278(97)80085-2)
- Wang, L., Park, H., Chhim, S., Ding, Y., Jiang, W., Queen, C. et al. (2012) A novel monoclonal antibody to fibroblast growth factor 2 effectively inhibits growth of hepatocellular carcinoma xenografts. *Mol. Cancer Ther.* **11**, 864–72, <https://doi.org/10.1158/1535-7163.MCT-11-0813>
- Monga, S.P. (2015) beta-Catenin Signaling and Roles in Liver Homeostasis, Injury, and Tumorigenesis. *Gastroenterology* **148**, 1294–310, <https://doi.org/10.1053/j.gastro.2015.02.056>
- Vilchez, V., Turcios, L., Marti, F. and Gedaly, R. (2016) Targeting Wnt/beta-catenin pathway in hepatocellular carcinoma treatment. *World J. Gastroenterol.* **22**, 823–32, <https://doi.org/10.3748/wjg.v22.i2.823>

- 28 Willyard, C. (2007) Researchers look for 'sweet' method to diagnose cancer. *Nat. Med.* **13**, 1267, <https://doi.org/10.1038/nm1107-1267>
- 29 Sauzay, C., Petit, A., Bourgeois, A.M., Barbare, J.C., Chauffert, B., Galmiche, A. et al. (2016) Alpha-fetoprotein (AFP): A multi-purpose marker in hepatocellular carcinoma. *Clin. Chim. Acta.* **463**, 39–44, <https://doi.org/10.1016/j.cca.2016.10.006>